VICCPHI1144-A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients with Advanced Solid Malignancies (IRB No. 110923).
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2017
At a glance
- Drugs AZD 4547 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 14 Jun 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 25 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2014 to 1 Mar 2015.